{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"6.0","value":"1.2"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"7.4","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Progression-free survival will be the number of days from study entry to progression or death of any cause, whichever comes first.\n\nProgression-free survival is survival with absence of progressive disease, defined by\n\n* An increase of 25% from lowest response value in any one or more of the following:\n\n  * Serum M-component (absolute increase must be \\>0.5 g/100 ml) \\*\n  * Urine M-component (absolute increase must be \\>200mg per 24 h)\n  * Only in patients without measurable serum and urine M-protein levels: the difference between involved and uninvolved FLC levels (absolute increase must be \\>100 mg/l)\n  * Bone marrow plasma cell percentage (absolute % must be \\>10%)\n* And / or:\n\n  * Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas\n  * Development of hypercalcemia (corrected serum calcium \\>11.5 mg/100 ml) that can be attributed solely to the plasma cell proliferative disorder","dispersionType":"95% Confidence Interval","groups":[{"description":"Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 3mg on day 1, 8, 15, 28","id":"OG000","title":"DL1 - 3mg Lxazomib"},{"description":"Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 3mg on day 1, 8, 15, 28","id":"OG001","title":"DL2 - 4mg Lxazomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"1 year from start of treatment","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}